Assignee
IMMUNE DESIGN CORP
US·14 granted patents·13 pending applications·34 citations·filing 2010–2021
Top patents by PatentIndex Score
27 records- 0188US11135283B2Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acidsIMMUNE DESIGN CORP·Filed 2016·Granted Oct 5, 2021·6 cites·20 claims
- 0287US8957047B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2014·Granted Feb 17, 2015·12 cites·40 claims
- 0383US9713635B2Materials and methods for producing improved lentiviral vector particlesIMMUNE DESIGN CORP·Filed 2013·Granted Jul 25, 2017·4 cites·32 claims
- 0480US8962593B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2014·Granted Feb 24, 2015·4 cites·18 claims
- 0577US10391157B2Materials and methods for producing improved lentiviral vector particlesIMMUNE DESIGN CORP·Filed 2017·Granted Aug 27, 2019·1 cites·30 claims
- 0676US10584356B2Multigenome retroviral vector preparations and methods and systems for producing and using sameIMMUNE DESIGN CORP·Filed 2018·Granted Mar 10, 2020·2 cites·25 claims
- 0776US9555099B2Vaccines for HSV-2IMMUNE DESIGN CORP·Filed 2013·Granted Jan 31, 2017·2 cites·14 claims
- 0875US10391164B2Vaccines for HSV-2IMMUNE DESIGN CORP·Filed 2016·Granted Aug 27, 2019·1 cites·9 claims
- 0972US10993956B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2019·Granted May 4, 2021·0 cites·11 claims
- 1071US9895435B2Vaccines for HSV-2IMMUNE DESIGN CORP·Filed 2013·Granted Feb 20, 2018·1 cites·14 claims
- 1170US11365230B2Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereofIMMUNE DESIGN CORP·Filed 2016·Granted Jun 21, 2022·1 cites·11 claims
- 1265US2022088177A1Retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acidsIMMUNE DESIGN CORP·Filed 2021·Application pending·0 cites
- 1365US2022054627A1Retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acidsIMMUNE DESIGN CORP·Filed 2021·Application pending·0 cites
- 1462US2020023057A1Vaccines for hsv-2IMMUNE DESIGN CORP·Filed 2019·Application pending·0 cites
- 1554US10342815B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2015·Granted Jul 9, 2019·0 cites·17 claims
- 1653US10993999B2Materials and methods for producing improved lentiviral vector particlesIMMUNE DESIGN CORP·Filed 2019·Granted May 4, 2021·0 cites·32 claims
- 1749US2015352135A1GLA Monotherapy for Use in Cancer TreatmentIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 1847US2022054611A1Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancerIMMUNE DESIGN CORP·Filed 2019·Application pending·0 cites
- 1946US2011064763A1Lentiviral vectors pseudotyped with a sindbis virus envelope glycoproteinIMMUNE DESIGN CORP·Filed 2010·Application pending·0 cites
- 2046US2016076055A1Lentiviral vectors pseudotyped with a sindbis virus envelope glycoproteinIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 2145US10179919B2Multigenome retroviral vector preparations and methods and systems for producing and using sameIMMUNE DESIGN CORP·Filed 2017·Granted Jan 15, 2019·0 cites·47 claims
- 2239US2015335733A1Immunogenic Composition and Methods of Using the Compositions for Inducing Humoral and Cellular Immune ResponsesIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 2337US2019119350A1Ny-eso-1 specific tcrs and methods of use thereofIMMUNE DESIGN CORP·Filed 2016·Application pending·0 cites
- 2437US2017196954A1Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vectorIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 2530US2016058852A1Immunotherapy of cancer through combination of local and systemic immune stimulationIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 2630US2016193326A1Vaccine Compositions for Drug AddictionIMMUNE DESIGN CORP·Filed 2014·Application pending·0 cites
- 2727US2016030459A1Compositions and methods for treating allergic conditionsIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IMMUNE DESIGN CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →